HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses

Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide

(2011) J Chang et al.   BRITISH JOURNAL OF CANCER

Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737

(2011) A. P. Wiegmans et al.   CANCER RESEARCH

Vorinostat-Induced Apoptosis in Mantle Cell Lymphoma Is Mediated by Acetylation of Proapoptotic BH3-Only Gene Promoters

(2011) S. Xargay-Torrent et al.   CLINICAL CANCER RESEARCH

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors

(2010) Cliona Grant et al.   Expert Review of Anticancer Therapy

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

(2010) Michael Dickinson et al.   INVESTIGATIONAL NEW DRUGS

Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?

(2008) V Labi et al.   CELL DEATH AND DIFFERENTIATION

Histone deacetylase inhibitors in lymphoma and solid malignancies

(2008) Walid Rasheed et al.   Expert Review of Anticancer Therapy

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

(2008) A. Newbold et al.   MOLECULAR CANCER THERAPEUTICS

HDAC3 overexpression and colon cancer cell proliferation and differentiation

(2007) Colleen C. Spurling et al.   MOLECULAR CARCINOGENESIS